Shareholders Vote in Favour of the Acquisition of Terranueva Pharma
The shareholders also elected the following directors by majority vote: Sylvain Aird, Marc-André Aubé, Pierre Ayotte, Patrice Boily, Alain Bureau, Louis Doyle, Rafael Percopo and Francisco Junior Perez. They also appointed PricewaterhouseCoopers LLP as the Company’s auditors.
In addition, further to a vote in favour by the shareholders (87.1%), the Common Shares will be listed on the Canadian Securities Exchange under the ticker symbol TEQ toward the beginning of December 2018 and will have been voluntarily delisted from the TSX Venture Exchange on or about November 27, 2018 once the acquisition and placement are closed.
The Company’s management is pleased to announce that the minimum financing requirement in the amount of $2,250,000 has been achieved in respect of the transaction.
Neither the Canadian Securities Exchange nor the TSX Venture Exchange Inc. has commented on the merits of the proposed transaction nor approved or disapproved of the contents of this press release.
Neither the Canadian Securities Exchange nor the TSX / NEX or their respective regulatory service providers (as this term is defined in their respective policies) assumes any responsibility for the adequacy or accuracy of this press release.
For more information, please contact:
For Terranueva Pharma Corporation:
Pierre Monet, CFO
Telephone: (514) 883-8733
For Axe Exploration Inc.
David Mc Donald, President
Telephone: (450) 622-5785